

## INDEX

- Academic centers, clinical trials, 6–7  
 Academic partnerships, 10, 12  
 Accelerators, historical perspective, 117  
 Accreditation programs, 118–119  
 Acquisition factors, influence of, 8, 48, 79  
 Acute treatment, 11  
 Adenocarcinomas, 17, 27, 55  
 ADNI, 79  
 Advanced Magnetics, 74  
 Advanced Technology Program (ATP), NIST, 119–120  
 Alzheimer's disease, 46, 134–135  
 American Association of Physicists in Medicine (AAPM), 118, 125  
 American College of Radiology Imaging Network (ACRIN), 79, 106  
 American Intergroup Trial 0139, 21  
 American Society of Clinical Oncology, 26  
 Amira, 77  
 Analysis of variance (ANOVA), 104  
 Analyst error, 8  
 Analyze, 89  
 Anesthesia, 4  
 Angiogenesis, 28, 62  
 Angiography, 75, 130  
 Animal models, 4, 74–75  
 Anthracycline, 29  
 Antiangiogenic therapy, 4, 7  
 Antibody-based imaging agent, 70  
 Anticancer drugs, 56  
 Antivascular therapy, 7  
 Application Hosting Working Group, 68, 86–90  
 Application programming interface (API), 77, 87  
 Archive (NCI), 89  
 Archives, 87  
 Atelectasis, 46  
 Attenuation, 41–42, 57–58  
 Automated analysis, 47  
 Automated volumetry (AV), 102  
 AVS Express, 77  
 Axial images, 54, 72–73, 97  
 Back-end processing servers, 87  
 Barentsz, Jelle, 85  
 Basic fibroblast growth factor (bFGF), 28  
 Bevacizumab, 20, 62  
 Bidimensional measurements, 53–54, 60–61, 103, 99–101  
 Bioinformatics, 134  
 Biological factors, influence of, 8  
 Biomarkers:  
   detection using radiological imaging software, 79–80  
   development, time requirements for, 12  
   *EGFR* gene, 27  
   industrialization of, 5, 10–11  
   new imaging, development of, 5–9, 68, 80  
   qualification of, 1–3, 6, 11  
   quantitative imaging techniques as, 14  
   quantitative software applications, 68  
   robustness of, 8  
   RRM1, 26  
   standardization for clinical trials, 6–8  
 Biomarkers Consortium, 3

*Quantitative Imaging Tools for Lung Cancer Drug Assessment*, Edited by James L. Mulshine and Thomas M. Baer  
 Copyright © 2008 John Wiley & Sons, Inc.

## 156 INDEX

- Biomedical imaging archive network (BIAN):  
 benefits of, 134–137  
 databases in molecular biology, 132–134, 137  
 implementation of, 137–139  
 overview of, 79, 131–132
- Biopsies, 44, 59, 72, 129
- Biotechnology industry, 68, 78, 90
- Blood-brain barrier, 29
- Boundary errors (Es), 45–46
- Brain tumors, 75
- Breast cancer, 27, 133–134
- Business models, 10, 12
- caBIG (Cancer Bioinformatics Grid), 68, 79,  
 88–90, 124–125, 129
- Calibration, of measurement instrumentation,  
 117–121
- Calipers, 54
- Cancer imaging, 11
- Cancer Research and Prevention Foundation  
 (CRPF):  
 functions of, 95, 124, 141  
 Reference Image Database to Evaluate  
 Response (RIDER), 123–130
- Candidates, comparison of, 7
- Canny edge detector, 45
- Capromab pendetide imaging, 70–73, 75
- Carboplatin, 22, 24–26
- Cardiovascular system, 11
- Case report forms, standard, 9
- Centers for Disease Control, 136
- Centralized image analysis, 9–10
- Central nervous system, 11
- Cetuximab, 27
- Chemoradiation, 18
- Chemoradioactivity, induction, 21
- Chemoradiotherapy, 21–22, 24
- Chemotherapy, *see specific chemotherapeutic  
 agents*  
 adjuvant, 18–20, 142  
 anthracycline-based, 29  
 concomitant, 22  
 consolidation, 22  
 customized, 26  
 cytotoxicity, 26, 63  
 induction, 21–22  
 neoadjuvant, 22  
 palliative, 18  
 platinum-based, 19, 26, 29  
 schedule of, 26  
 survival benefits of, 25–26  
 toxicity, 26, 28
- Chronic myelogenous leukemia, 26
- Circulation, 83
- Cisplatin, 19, 22–26, 29
- Cisplatin-etoposide chemotherapy, 29
- Clinical environment, 77–78
- Clinical Laboratory Improvement Amendment  
 (CLIA), 138
- Clinical trials, *see specific phases of clinical trial*  
 endpoints, 7–10, 12–14  
 image acquisition and analysis, 9  
 imaging challenges, 11–13  
 implementation of, 12  
 multiple sites, 6–7  
 patient stratification, 5  
 radiological imaging software applications,  
 79–80  
 site selection criteria, 6–7  
 sponsoring company, role of, 9–10  
 standard imaging protocols, 3, 6–8  
 work flow, 10
- Collaborative research, 3, 9, 68, 77, 79–80
- Combix, 74
- Comorbidity, 26
- Complete response (CR), 40, 43, 54, 62, 97
- Computed tomography (CT):  
 applications, generally, 11  
 contrasting agents, 69  
 helical, 145  
 high-resolution, 3–6, 19, 42, 58, 68  
 historical perspective, 5  
 low-dose scan, 101  
 lung cancer drug development and evaluation,  
 22, 39–49, 120–121, 145  
 multislice scanner (MSCT), 7, 100–102  
 reproducibility of, 8  
 resolution, 71  
 scan reconstruction algorithms, 57  
 serial, 124, 126  
 SPECT compared with, 72–73  
 spiral, 95, 135, 141, 143–144, 151–152  
 standard protocols, 56–57  
 surrogate imaging endpoints, 43–47  
 thin-section, 60  
 traditional image-based response assessment, 53  
 volumetric. *See Volumetric CT imaging for  
 response assessment in lung cancer*
- Computer-aided diagnosis (CAD):  
 lung cancer, detection and diagnosis, 58–59,  
 100, 106, 125, 129–130, 143–149, 152  
 research studies, 43, 48–49, 87, 131  
 therapeutic response assessment, 103, 106
- Computer software image segmentation, 57–58
- Conference of Radiation Control Program  
 Directors (CRCPD) Program, 118
- Confidence interval, 105
- Contrast agents, 8, 13, 54, 69, 119–120

- Contrast mechanisms, development of, 6
- Cornell therapy assessment database, 48–49
- Cost-benefit relationship, 12–13
- Cranial irradiation, 18, 28
- Critical Path Initiative, 2–3, 6, 150
- Crohn's disease, 11
- Cross-product measurements, 61
- Cross-sectional images, 55
- CT 40 Cardiac Viewer, 82–83
- Custom imaging applications, 75
- Cyclophosphamide, 23
- Cytotoxicity, chemotherapeutic agents, 26, 56, 63
  
- Data, generally:
  - collection, 6–7, 12, 84
  - sharing, 150–151
  - storage, 9
  - transfer, 9
- Databases:
  - linking procedures, 85
  - molecular biology, 132–134, 137
  - multistudy standardized imaging, 11
  - public access, 123–130
  - validation in therapy assessment, 48–49
- Decision-making tools, 2–3, 7, 48
- Delphi, 77
- Dental technology, 114
- Department of Energy, 137
- Diagnostic radiology, 7
- DICOM:
  - applications, 84, 86, 124, 126, 143
  - WG-23 application hosting standard, 68, 86–90
- Differential geometry operators, 45
- Diffuse disease, 41
- Diffusion-weighted imaging, 6
- Digital editing tools, 47
- Digital image data, 119
- Disease:
  - morphological descriptors, 5, 11
  - progression, 40
- Docetaxel, 23, 26, 99
- Dosage:
  - impact of, 4
  - mammography standards, 118
  - scheduling, 4
  - standards, generally, 113
- Dosimetry, patient-specific, 69
- Drug development:
  - business model, 10
  - clinical trials, 3, 5–9
  - exploratory IND, 13
  - lung cancer, 11, 39–49, 135–136, 141–152
  - oncology, 13
  - phantom development, 150–151
  - preclinical imaging models, 4
  - premarket approval application (PMAA), 146
  - quantitative imaging, 10
  - targeted therapy, 27–28
  - translational imaging, 3–4, 7
- Drug discovery, 55–56
- Duet camera, 72
- Dynamic contrast-enhanced computed tomography (DCE-CT), 7, 13
- Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), 4, 7–8, 11
  
- e.Cam+, 72
- Eclipse, 77
- Efficacy, 5
- EGFR* gene, 27, 56
- Elderly population, chemotherapeutic recommendations, 26
- Emphysema, 130
- Endophtalmos, indications of, 24
- Eosin, 76
- Epidermal growth factor receptor (EGFR) pathway, 27, 60
- Epothilones, 26
- Equipment failure, 8
- Equipment vendors, 10, 12
- ERCC1 (excision repair cross-complementary-1 protein), 20
- Erlotinib, 20, 27, 56, 62, 99
- Esophagitis, 23, 29
- Etoposide, 24, 29
- European Organization for Research and Treatment of Cancer (EORTC), 98
- Exploratory IND, 13
- Extensible imaging platform (XIP), 68, 88–90
  
- Fano, Ugo, 114
- Feasibility studies, 9, 12
- Ferumoxtran-10 imaging, 74–75, 84–85
- Ferumoxytol, 75
- Field strength, 7
- Fluorine-18-labeled deoxyglucose positron-emission tomography (FDG-PET), 3, 5, 8, 12–13, 49
- Food intake, 8
- Four-dimensional imaging, 83
- Functional imaging technologies, 5, 11
  
- Gefitinib, 27, 56, 62, 99
- Gemcitabine, 26, 99
- Genbank, 133
- Genetic mutations, 27, 99
- Genomics, 69
- Go/no-go decisions, 4

## 158 INDEX

- Graphical user interfaces (GUIs), 77
- Gray (Gy), 113
- Half-life, 119
- Hardware system, 4, 7–8, 12
- Health-*e*-Child project, 80
- Health Insurance Portability and Accountability Act (HIPAA), 151
- Heart rate, 8
- Hematoxylin, 76
- High-spatial-resolution algorithms, 57
- Horner's syndrome, 24
- Hounsfield units (HU), 41
- Human editing, 47
- Human Genome Project, 133
- Hybrid analysis, 46–47
- Hyperfractionation, 29
- IDL, 77
- Image analysis:
  - identification of methodologies, 11
  - influential factors, 8
- Image Database Resource Initiative (IDRI), 125, 127
- Image quality, 78
- Imaging:
  - acquisition and analysis, 5, 7, 9
  - benefits of, 3–4
  - biomarkers, development of, 5–6, 12
  - early development of, 4
  - hardware, 4, 7–8, 12
  - implementation, practical, 9–10
  - late development of, 4–5
  - reproducibility, 7–9, 102
  - standardization for clinical trials, 6–8
  - types of, 3, 5
- Imaging core labs (ICLs), 5, 9–13
- Imaging industry:
  - role in biomarker development, 10–11
  - trends in, 1–2, 9
- Imaging networks, 79
- Imaging software development:
  - application linking procedures, 84–85
  - bottlenecks, types of, 75–80
  - compilation time, 84–85
  - interoperability, 68
  - ivRAD, 82–86, 89
  - rapid application development (RAD), 68, 82–86
  - run time, 84
  - startup time, 86
  - XIP, 68, 88–90
  - work flows, 89
- Imaging Workspace, 79, 88–90
- Immature technologies, 12
- Immunologic agents, 71
- Implementation plan, 9–10
- In vitro diagnostics, 138
- In vivo studies, 101–102, 138
- Industry partnerships, 12
- Information Technology Laboratory (ITL), NIST, 119–120
- Insight Segmentation and Registration Toolkit (ITK), 76
- Institutional Review Board (IRB), 151
- Integrated development environments (IDEs), 77
- Interagency Working Group on Digital Data, (IWG), 138
- International Adjuvant Lung Trial (IALT), 20
- International Commission on Radiation Units and Measurements, 113
- Interpretation, 10
- Intraobserver/interobserver, generally:
  - misclassification, 41
  - variability, 54, 62, 100, 102
- Intravenous contrast agents, 54
- Intrinsic variability, 62
- Ionization radiation, 113, 116
- Iressa, 56
- Irinotecan, 29
- Iron oxide agents, 74
- ivRAD toolkit, 82–86, 89
- Joint replacement, 136–137
- K-RAS mutations, 56
- $K^{\text{trans}}$ , 4
- Large cell carcinomas, 17
- Largest perpendicular diameter (LPD), 97
- Lesion(s):
  - boundaries, 45
  - heterogeneity, 6, 12
  - measurement of, 54–55
  - metastatic, 40
  - region growth, 44
  - segmentation, 47
  - size, 8
- Limits of agreement (LoA), 103–104
- Localized disease, 18
- Lomustine, 23
- Long-term outcomes, 11
- Lung cancer:
  - attenuation value, 41–42
  - characterized, 135, 142
  - clinical trials, 11
  - computer applications, 58–61
  - CT imaging, 120–121

- cure rate, 55  
 current treatments and evaluation of, 99–100  
 disease progression, 40  
 drug development progress, 141–152  
 drug efficacy, 39  
 epidemiology, 7  
 late-stage, 42  
 nodule segmentation, 58  
 quantitative CT therapy, 42  
 radiotherapy, 22  
 response assessment, volumetric CT imaging, 53–63  
 therapeutic response criteria, statistical factors, 96–99, 102–104  
 volumetric assessment using multislice CT scanners and CAD algorithms, 95–107
- Lung Image Database Consortium (LIDC), 79, 125, 127, 143–144
- Lung Nodule Image Database Consortium, 106
- Lung pleura, estimation errors (Ep), 45–46
- Lymph nodes, 18, 21–22, 74, 76, 83–84
- Lymphoma, staging of, 5
- Macrophages, 75
- Magnetic resonance imaging (MRI):  
 applications, 5–6, 13, 53, 69, 71–74, 76, 134–136  
 contrast agents, 119–120
- Maintenance therapy, 29
- Malignancy, 58, 84, 102
- Mammography Quality Standards Act (MQSA), 117
- Mammography standards, 117–119
- Manufacturer limitations,  
 cross-center/cross-scanner, 5
- Mathematical analysis, 134
- Matuzumab, 27
- Maximum axial diameter (MD), 97–98
- Measurement:  
 accuracy, 47  
 errors, 98, 102  
 variability, influential factors, 8, 98
- Memorial Sloan-Kettering Cancer Center, 60
- Mesothelioma, 61
- Meta analyses, applications of, 11, 24–25
- Metabolic imaging technologies, 5, 11
- Metastatic disease, 18, 21, 27, 29, 57, 129
- Methodology development programs, 6
- MeVisLab, 77
- MGH, 74
- Microarray technology, 133
- MIRC software (RSNA), 79, 89, 126–127
- Misclassification, rates of, 41
- Mitomycin, 25
- Molecular imaging:  
 agents, 13  
 applications, 68–69, 90  
 with capromab pendetide, 70–73, 75  
 with ferumoxtran-10, 74–75, 84–85  
 historical perspective, 69
- Molybdenum, 118
- Monoclonal antibodies, 27–28
- Morbidity, 69
- Morphological imaging technologies, 11
- Morphology, volumetric CT imaging, 57–58
- Morphometry, high-resolution CT, 5
- Mortality rates, lung cancer, 16
- Motion, 8
- MR Lymph Node segmentation task card, 83–84
- Multicenter clinical trials, 55
- Multimodality fusion, 68
- Multiple sclerosis, 75
- Multiple site studies, 5
- Multireader multicase (MRMC) analysis, 48
- Multisite collaboration, 77
- Multislice scanners, 7, 100–102
- Multivariate analysis, 22
- Musculoskeletal diseases (MSDs), 136
- MX-8000/MX-8000 IDT scanner, 72
- Myelosuppression, 29
- Myosis, indications of, 24
- National Bureau of Standards (NBS), 112–113
- National Cancer Institute (NCI):  
 functions of, 68, 79, 88–90, 98, 106, 124  
 RIDER/LIDC database, 11, 48–49, 123–130
- National Institute of Biomedical Imaging and Bioengineering (NIBIB), 124, 127
- National Institutes for Standards and Technology (NIST), quantitative biomedical imaging:  
 CT imaging in lung cancer, 120–121  
 current efforts, 117–119, 137  
 future directions for, 119–120  
 historical perspectives, 112–117  
 overview, 111–112
- National Institutes of Health, 106, 137
- National Science Foundation, 137
- NCCTG, 79
- Needle biopsy, 44
- New drug indication (NDI), 135
- Noise, 45
- Non-Hodgkin's lymphoma, 3
- Non-small cell lung cancer (NSCLC):  
 characterized, 3, 17, 99  
 high-resolution CT scans, 59  
 induction, 21, 23

## 160 INDEX

- Non-small cell lung cancer (NSCLC) (*Continued*)  
 metastatic dissemination, 21  
 prevalence of, 99  
 stage categories, 18  
 survival rates, 22–23, 27–28, 99  
 treatment of, by stage, 18–28  
 trimodality therapy, 21
- NTROI (Network for Translational Research in Optical Imaging), 79–80
- Nuclear medicine imaging, 71, 121
- Nuclear Regulatory Commission, 119
- Observer editing, 47
- Occult recurrent disease, 70
- Oncology, *see specific types of cancers*  
 biomarkers, 3, 10–11  
 drug evaluation methods, RECIST, 39–49
- OpenGL (open graphics library), 86, 89
- Open-source development community, 89–90
- Operator error, 8
- Optical imaging, 68
- Organ transplantation, 75
- Osteoarthritis, 136
- Outcome studies, 11
- Paclitaxel, 25–26, 99
- PACS (picture archiving and communication systems), 68, 87, 127
- Palliative care, non-small cell lung cancer, 18, 24–28
- Panitumumab, 27
- Parallel imaging, 7
- Partial response (PR), 40–41, 43, 48, 54, 62, 97
- Partial-volume method, 57
- Patient positioning, 8
- Pemetrexed, 26
- Pertuzumab, 27
- Phantom studies, 48, 101, 151–152
- Pharmaceutical industry, 11, 68, 78, 90, 125–126
- Phase 1/Phase 2/Phase 3 trials, 4, 6–7, 151
- Philips, 72
- Physiological imaging methods, 5
- Plaque, 75
- Platform noise, 8
- Platinum-etoposide chemotherapy, 29
- Plug-in technologies, 80–81, 87–88, 90
- Pneumonectomy, 21
- Positron-emission tomography (PET):  
 characterized, 5–7, 13  
 computed tomography (PET-CT), 11, 22, 49, 124–125, 128  
 image quality, 78  
 $[^{15}\text{O}]\text{H}_2\text{O}$  PET, 7
- Postimaging processing, 73
- Postprocessing procedures, 79, 81
- Power Doppler ultrasound, 7
- Product development, 3, 5
- Progressive disease (PD), 40, 43, 48, 54, 62, 97
- ProstaScint, 70
- Prostate cancer, 70–72
- Prostate-specific antigen (PSA), 72
- Prostate-specific membrane antigen (PSMA), 70
- Protein Data Bank (PDB), 132–133
- Protein mass spectrometry, 133–134
- Protocols:  
 failure of, 8  
 standard. *See* Standardized imaging protocols
- Ptosis, indications of, 24
- Qt, 77
- Quality assurance, 9, 78
- Quality of life, 112
- Quantitative imaging:  
 future challenges for, 49  
 methodologies, 1  
 overview of, 39–43  
 surrogate imaging endpoints, 43–47  
 validation, 48–49
- Quantitative reverse-transcription polymerase chain reaction (qRT-PCR), 26
- Quantitative therapy assessment algorithms, 47–49
- RAD/plugin initiative, 68, 75, 80–82, 90
- Radiation therapy:  
 dose-fractionation schedules, 21–24  
 palliative, 18  
 radical, 21
- Radiographic follow-up, 59
- Radioimmunoassays, 138
- Radioimmunoscintigraphy, 71
- Radiological imaging software bottlenecks:  
 biomarkers and clinical trial domain, 79–80  
 commercial domain, 78–79  
 RAD/plugin as solution to, 80–82  
 research domain, 75–78
- Radiological Society of North America (RSNA), 112, 124–125
- Radiological software development. *See* Imaging software development
- Radiological software standards:  
 DICOM WG-23 application hosting standard, 86–90  
 need for, 68–69
- Radiotherapy:  
 definite, 22, 24  
 dose-escalation, 22  
 thoracic, 29

- Radium, 115–116
- Rapid application development (RAD):  
defined, 68, 82–86  
visual programming for, 77
- Rapidscreen RS-20000D, 100
- Reader variance, 47, 102–105
- Registration-based assessment algorithms, 44, 46–47
- Renal cancer, 26
- Repeatability, significance of, 106
- Repeatability coefficient (RC), 103
- Reproducibility, significance of, 7–9, 102, 106, 150–151
- Rescanning, 8
- Response assessment:  
traditional image-based, 53–55  
volumetric CT imaging, 53–63
- Response Evaluation Criteria in Solid Tumors (RECIST), 5, 39–43, 53, 59, 96–99, 102, 143–144
- Reticuloendothelial system (RES), 74
- Return on investment (ROI):  
decision, 8  
impact of, 14  
influential factors, 12
- Rheumatoid arthritis, 11
- Rhodium, 118
- Ribonucleotide reductase subunit M1 (RRM1) protein, 26
- RIDER (Reference Image Database to Evaluate Response), 79, 123–130
- Robustness, significance of, 5, 7–8
- ROC analysis, 48
- Sample size:  
estimation guidelines, 104–106  
significance of, 8, 96
- SCIRun, 77
- Segmentation-based assessment algorithms, 44, 46–47
- Shoulder pain, indications of, 24
- Siegel, Eliot, 88
- Siemens, 68, 72, 80, 82–83
- Sievert (Sv), 113
- Signal-to-noise ratio, 120–121
- Signal transduction pathways, 69
- Single-photon-emission CT (SPECT), 5–6, 13, 69, 71–73, 78
- Site imaging facilities:  
assessment of, 9  
education modules, 9  
standardized training in, 5, 10
- Site selection, 6–7
- Slice positioning, 8
- Slice thickness, 45
- Small cell lung cancer (SCLC), 18, 28–30
- SOAP, 80
- Soft tissue, 41
- Software libraries, integration of, 75–77
- Software programs:  
diversity of, 12  
measurement variability, 8  
transparency of, 12–13
- Southwest Oncology Group Study, 23–24
- Spatial resolution, 54
- Spiculation, 41
- Sponsoring company, role of, 9–10
- Squamous cell carcinomas, 17
- Stable disease (SD), 40–41, 43, 48, 54, 62, 97
- Standard deviation (SD), 103–5
- Standardization, radiological software, 68, 86
- Standardized imaging protocols, 3, 6–8
- Standard reference materials (SRMs), 119, 138
- Statistical analysis, 10
- Stereotactic radiotherapy, 19
- Such-dimensional Hessian, 45
- Surgical treatment, 18–19, 21, 24, 56
- Synchrotron:  
NIST SURF III Ultraviolet Radiation Facility, 117  
180-MeV NBS, 116–117
- Syngo, 83–84
- Tarceva, 56
- Targeted therapies, 27–28, 54
- Taxanes, 26, 99
- Taylor, Laurison S., 113
- Technical variability, 148–149
- Technological advances:  
dental x-rays, 114  
prototypes, 68, 83, 87, 114  
radiological software, 68
- Therapeutic response assessment, 103
- Therapy assessment:  
approaches, 46–47  
interval, 39, 42, 59
- Thoracic irradiation, 29
- Three-dimensional visualization, 68, 73
- Time of day, significance of, 8
- Time series studies, 4
- Topoisomerase inhibitors, 27
- Tracers, 6, 8, 13
- Training programs, radiological imaging software, 78
- Translational imaging, 3–4, 7
- Transparency, 12–13
- Transverse images, 53
- Trimodality therapy, 21

**162** INDEX

- Tumor:
  - burden, 46, 61
  - chemoresponsive, 29
  - control strategies, 22
  - growth, 8, 28
  - molecular profile of, 20
  - physiology and microstructure, 6
  - segmentation, 44, 46, 61–62
  - size and shape changes, 41, 49, 56, 61
  - size measurements, 10, 96
  - stage of, 19
  - traditional measurement criteria, 53
  - volume, 4, 40, 54, 57, 120–121, 149
- Tyrosine kinase inhibitors (TKIs), 27, 62
- Ultrasound, historical perspective, 5
- Unidimensional measurement, 53–54, 60–61, 99–101, 103
- U.S. Food and Drug Administration (FDA), 70, 81, 88–90, 100, 117–119, 124, 127, 135, 142, 145, 150
- UPICT initiative, 79
- Validation:
  - imaging software development, 77
  - therapy assessment, 48–49
- Vascular boundaries (Ev), 45–46
- Vascular endothelial growth factor (VEGF), 28
- Vendor-University research, radiological imaging software, 78
- Vevacizumab, 28, 99
- Vinblastine, 23–24
- Vinca alkaloids, 26
- Vindesine, 25
- Vinorelbine, 25–26, 99
- VisiQuest, 77
- Visual C++, 73
- Visualization Data Explorer, 77
- Visualization Toolkit (VTK), 73
- Visual Studio, 77
- Volumetric assessment, 99–100
- Volumetric CT imaging for response assessment in lung cancer:
  - future challenges for, 61–63
  - standard protocols, 56–57
  - technological advances, 55–58
  - traditional image-based response assessment distinguished from, 53–55
- Volumetric measurement algorithms, 45–46
- War on Cancer, 142
- Washington University, radiological software development, 68
- Work flows, 89
- Workstation, radiological imaging software:
  - deployment issues, 78
  - plug-in technologies, 80–81, 83
- World Health Organization (WHO), 39, 41, 53, 59, 96–99, 144
- X-rays:
  - anode materials, 118
  - mammography, 117–119
  - panoramic, 114
  - patient exposure to, 120–121
  - spectroscopy, 113
  - technicians, exposure to, 112–113
- XML, 80
- z direction, 54
- Zevalin, 69